QSAM Biosciences, Inc. announced the addition of Rutgers Cancer Institute of New Jersey (RCINJ) as a clinical trial site approved to begin enrolling patients into the Phase 1 study evaluating CycloSam® in treating patients with bone cancer that either originated in or has metastasized to the bone. RCINJ is part of Rutgers Health and New Jersey's only National Cancer Institute (NCI) – designated Comprehensive Cancer Center, an elite recognition that is granted competitively to institutions based on their scientific leadership, resources, and outstanding track record of research discoveries and ability to translate these discoveries to benefit cancer patients. RCINJ is QSAM's second trial site approved to enroll patients in this study.

QSAM's study is a multiple center, dose escalation clinical trial intended to determine the maximum tolerated dose of CycloSam® in patients, and also assess early efficacy signals. Patients with bone cancer that has metastasized from the breast, prostate, lung, or other organs are eligible to enroll in the study. Additionally, osteosarcoma and Ewing's Sarcoma bone cancer patients, diseases that mostly affect children and young adults, are also eligible.